

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	ST6-N-acetylgalactosaminide α -2,6-sialyltransferase 5 (ST6GALNAC5)	<p>Studies in mice and in cell culture suggest that increasing ST6GALNAC5 expression could help treat gliomas. In a human glioma cell line, vector-based overexpression of ST6GALNAC5 reduced invasiveness compared with that in human glioma cell lines treated with empty vector. In mice implanted with ST6GALNAC5-overexpressing glioma cells, tumors were between one-fifth and one-fourth the size of those in vector-transfected control cells. Next steps could include identifying compounds that increase ST6GALNAC5 expression in glioma cells.</p> <p>SciBX 3(28); doi:10.1038/scibx.2010.852 Published online July 22, 2010</p>	Patent and licensing status unavailable	<p>Kroes, R.A. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online June 28, 2010; doi:10.1073/pnas.0909862107 Contact: Joseph R. Moskal, Northwestern University, Evanston, Ill. e-mail: j-moskal@northwestern.edu</p>